{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:37:57Z","timestamp":1769578677572,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI137472"],"award-info":[{"award-number":["R01AI137472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI139092"],"award-info":[{"award-number":["R01AI139092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI157975"],"award-info":[{"award-number":["R01AI157975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.trsl.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:01:57Z","timestamp":1651096917000},"page":"11-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge"],"prefix":"10.1016","volume":"248","author":[{"given":"Juan","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbo","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby E.","family":"Odle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2022.04.007_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0002","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.trsl.2022.04.007_bib0003","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41423-021-00752-2","article-title":"Neutralizing antibodies for the prevention and treatment of COVID-19","volume":"18","author":"Du","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2022.04.007_bib0004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14728222.2020.1820482","article-title":"Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2","volume":"25","author":"Jiang","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.trsl.2022.04.007_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-021-00523-5","article-title":"SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2022.04.007_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2022.04.007_bib0008","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2022.04.007_bib0009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2022.04.007_bib0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/ciab283","article-title":"Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco","volume":"74","author":"Peng","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2022.04.007_bib0011","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0012","article-title":"The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: a population based ecological study","volume":"1","author":"Freitas","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.trsl.2022.04.007_bib0013","article-title":"Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study","volume":"12","author":"Allen","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.trsl.2022.04.007_bib0014","article-title":"International risk of SARS-CoV-2 Omicron variant importations originating in South Africa","volume":"2021.12.07.21267410","author":"Bai","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.trsl.2022.04.007_bib0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.15585\/mmwr.mm7109e1","article-title":"SARS-CoV-2 B.1.1.529 (Omicron) variant transmission within households - Four U.S. Jurisdictions, November 2021-February 2022","volume":"71","author":"Baker","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2022.04.007_bib0016","doi-asserted-by":"crossref","DOI":"10.3201\/eid2806.220515","article-title":"Introduction and rapid spread of SARS-CoV-2 Omicron variant and dynamics of BA.1 and BA.1.1 sublineages, Finland, December 2021","volume":"28","author":"Vauhkonen","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.trsl.2022.04.007_bib0017","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"CMMID COVID-19 Working Group, et\u00a0al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0018","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1016\/j.cell.2021.04.025","article-title":"Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant","volume":"184","author":"Deng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2022.04.007_bib0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2022.04.007_bib0020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.15585\/mmwr.mm7043e1","article-title":"Severity of disease among adults hospitalized with laboratory-confirmed COVID-19 before and during the period of SARS-CoV-2 B.1.617.2 (Delta) predominance - COVID-NET, 14 States, January-August 2021","volume":"70","author":"Taylor","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2022.04.007_bib0021","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101146","article-title":"Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021","volume":"26","author":"Espenhain","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.trsl.2022.04.007_bib0022","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.15585\/mmwr.mm705152e3","article-title":"Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) variant cluster - Nebraska, November-December 2021","volume":"70","author":"Jansen","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2022.04.007_bib0023","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2022.04.007_bib0024","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104820","article-title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2","volume":"179","author":"Tai","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trsl.2022.04.007_bib0027","doi-asserted-by":"crossref","first-page":"e64815","DOI":"10.7554\/eLife.64815","article-title":"The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates","volume":"10","author":"Ye","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.trsl.2022.04.007_bib0028","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.trsl.2022.04.007_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009897","article-title":"Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection","volume":"17","author":"Geng","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2022.04.007_bib0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-022-04630-3","article-title":"Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19","volume":"605","author":"Roy Wong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0031","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0032","article-title":"Transmission of Omicron (B.1.1.529) - SARS-CoV-2 variant of concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19","volume":"18","author":"Wong","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.trsl.2022.04.007_bib0033","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.trsl.2022.04.007_bib0034","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on immunization practices' interim recommendation for use of Moderna COVID-19 vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2022.04.007_bib0035","article-title":"Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: a systematic review","author":"Amanzio","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.trsl.2022.04.007_bib0036","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2022.04.007_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2022.04.007_bib0038","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.trsl.2022.04.007_bib0039","first-page":"1327","article-title":"Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-alpha inhibitors","volume":"2","author":"Chen","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.trsl.2022.04.007_bib0040","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2022.04.007_bib0041","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","volume":"29","author":"Shen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.trsl.2022.04.007_bib0042","doi-asserted-by":"crossref","first-page":"e2277","DOI":"10.1002\/rmv.2277","article-title":"Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: a systematic review of in vitro studies","volume":"32","author":"Noori","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.trsl.2022.04.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01313-21","article-title":"Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2022.04.007_bib0044","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-021-03610-3","article-title":"Daily briefing: Omicron was already spreading in Europe","author":"Graham","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3201\/eid2802.212422","article-title":"Probable transmission of SARS-CoV-2 Omicron variant in Quarantine Hotel, Hong Kong, China, November 2021","volume":"28","author":"Gu","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.trsl.2022.04.007_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-021-03592-2","article-title":"Omicron is supercharging the COVID vaccine booster debate","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.04.007_bib0047","first-page":"eabl6015","article-title":"SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques","volume":"8","author":"Dalvie","year":"2022","journal-title":"Sci Av"},{"key":"10.1016\/j.trsl.2022.04.007_bib0048","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/vaccines10020307","article-title":"Induction of broadly cross-reactive antibodies by displaying receptor binding domains of SARS-CoV-2 on virus-like particles","volume":"10","author":"Chang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trsl.2022.04.007_bib0049","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2022.03.001","article-title":"Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants","volume":"569","author":"Mi","year":"2022","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2022.04.007_bib0050","unstructured":"Organization Health Organization. Tracking SARS-CoV-2 variants. 2022. Available at: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"10.1016\/j.trsl.2022.04.007_bib0051","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2022.04.007_bib0052","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2022.04.007_bib0053","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41423-022-00837-6","article-title":"Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant","volume":"19","author":"Zhang","year":"2022","journal-title":"Cell Mol Immunol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:45:18Z","timestamp":1761828318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524422000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"alternative-id":["S1931524422000937"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2022.04.007","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}